Progenitor cell therapy describes the use of multipotent cells of various cell lineages (autologous or allogeneic) for tissue repair and/or regeneration. Progenitor cell therapy is being investigated for the treatment of damaged myocardium resulting from acute or chronic ischemia and for refractory angina. The mechanism of benefit after treatment with progenitor cells is not entirely understood. Differentiation of progenitor cells into mature myocytes and engraftment of progenitor cells into areas of the damaged myocardium have been suggested in animal studies using tagged progenitor cells; however, there is controversy concerning whether injected progenitor cells engraft and differentiate into mature myocytes in humans to the degree that might result in clinical benefit.
Progenitor cell therapy for the treatment of damaged myocardium, including, but not limited to the use of skeletal myoblasts and hematopoietic stem cells is considered investigational.
Infusion of growth factors (i.e., granulocyte colony stimulating factor [GCSF]) as a technique to increase the numbers of circulating hematopoietic stem cells for the treatment of damaged myocardium is considered investigational.
Any specific products referenced in this policy are just examples and are intended for illustrative purposes only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available. These examples are contained in the parenthetical e.g. statement.
We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits, or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the Medical Policy and a health plan, the express terms of the health plan will govern.
Published evidence-based studies and support by professional organizations regarding the utilization of progenitor cell therapy for the treatment of damaged myocardium are lacking. Progenitor cell therapy for the treatment of damaged myocardium is a rapidly evolving field with a number of areas of substantial uncertainty including patient selection, cell type, and procedural details (e.g., timing and mode of delivery).
Afzal, M.R., Samanta, A., Shah, Z, Jeevanantham, V., Abdel-Latif, A., Zuba-Surma, E.K., et al. (2015). Adult bone marrow cell therapy for ischemic heart disease: evidence and insights from randomized controlled trials. Circulation Research, 117 (6), 558-575. Abstract retrieved July 30, 2015 from PubMed database.
American College of Cardiology Foundation & American Heart Association. (2013). 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. Retrieved May 10, 2017 from http://circ.ahajournals.org.
Bartunek, J., Terzic, A., Davison, B.A., Flippatos, G.S., Radovanovic, S., Beleslin, B., et al. (2017). Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double-blind, sham-controlled CHART-1 clinical trial. European Heart Journal, 38 (9), 648-660. (Level 1 evidence)
BlueCross BlueShield Association. Evidence Positioning System. (6:2020). Progenitor cell therapy for the treatment of damaged myocardium due to ischemia (2.02.18). Retrieved February 11, 2021 from https://www.evidencepositioningsystem.com/. (24 articles and/or guidelines reviewed)
Gyöngyösi, M., Wojakowski, W., Lemarchand, P., Lunde, K., Tendera, M., Bartunek, J. (2015). Meta-analysis of cell-based cardiac studies (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circulation Research, 116 (8), 1346-1360. (Level 1 evidence)
Lalu, M.M., Mazzarello, S., Zlepnig, J., Dong, Y., Montroy, J., McIntyre, L., et al. (2018). Safety and Efficacy of Adult Stem Cell Therapy for Acute Myocardial Infarction and Ischemic Heart Failure (SafeCell Heart): A Systematic Review and Meta-Analysis. Stem Cells Translational Medicine, 7 (12), 857–866. (Level 2 evidence)
Xiao, C., Zhou, S., Liu, Y., & Hu, H. (2014). Efficacy and safety of bone marrow cell transplantation for chronic ischemic heart disease: a meta-analysis. Medical Science Monitor, 20, 1768-1777. (Level 1 evidence)
Xu, R., Ding, S., Zhao, Y., Pu, J., & He, B. (2014). Autologous transplantation of bone marrow/blood-derived cells for chronic ischemic heart disease: a systematic review and meta-analysis. Canadian Journal of Cardiology, 30 (11), 1370-1377. Abstract retrieved May 9, 2017 from PubMed database.
Zhu, K., Li, J., Wang, Y., Luo, J., Guo, C., et al. (2015). Intramyocardial autologous bone marrow-derived stem cells injection for ischemic heart disease ineligible for revascularization: a systematic review and meta-analysis. Archives of Medical Research, 46 (4), 286-295. Abstract retrieved July 30, 2015 from PubMed database.
ORIGINAL EFFECTIVE DATE: 4/12/2007
MOST RECENT REVIEW DATE: 4/8/2021
Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.
This document has been classified as public information.